VCELVericel Corporation

$2B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+92.6% YoY

Gross Profit

$10M57.5% margin

Operating Income

-$4M-24.0% margin

Net Income

-$8M-42.5% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

-22.8%

Cash Flow

Operating Cash Flow

$405,000

Free Cash Flow

$221,000

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$52M

Total Liabilities

$31M

Stockholders' Equity

$21M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$9M	+92.6%
Gross Profit	$10M	$2M	+360.1%
Operating Income	-$4M	-$10M	+55.1%
Net Income	-$8M	-$10M	+21.7%

Revenue Segments

Epicel

$6M81%

Implants

$1M14%

Biopsy Kits

$436,0006%

VCEL Q1 2018 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena